Actinium Pharmaceuticals (ATNM) Accumulated Depreciation (2019 - 2024)
Actinium Pharmaceuticals (ATNM) posted quarterly Accumulated Depreciation of $891000.0 for Q4 2024, up 28.39% year-over-year from $694000.0 in Q1 2024, and up 28.39% quarter-over-quarter from $694000.0 in Q4 2023.
Actinium Pharmaceuticals (ATNM) Accumulated Depreciation (2019 - 2024) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Accumulated Depreciation for 4 consecutive years, with $891000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Accumulated Depreciation rose 28.39% year-over-year to $891000.0; the TTM figure through Dec 2024 stood at $891000.0 (up 28.39% YoY), while the FY2024 annual figure was $891000.0, up 28.39% from the prior year.
- Accumulated Depreciation advanced to $891000.0 in Q4 2024 per ATNM's latest filing, from $694000.0 in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $891000.0 in Q4 2024 and bottomed at $249000.0 in Q1 2020.
- Historically, Accumulated Depreciation has averaged $611333.3 across 3 years, with a median of $694000.0 in 2023.
- On a YoY basis, Accumulated Depreciation climbed as much as 28.39% in 2024 and fell as far as 28.39% in 2024.
- Actinium Pharmaceuticals' Accumulated Depreciation stood at $249000.0 in 2020, then soared by 178.71% to $694000.0 in 2023, then climbed by 28.39% to $891000.0 in 2024.
- Business Quant data shows ATNM's Accumulated Depreciation at $891000.0 in Q4 2024, $694000.0 in Q4 2023, and $249000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 891,000.00 |
| Dec 31, 2023 | 694,000.00 |
| Mar 31, 2020 | 249,000.00 |
| Dec 31, 2019 | 237,000.00 |